Hussman Strategic Advisors’s NovoCure NVCR Stock Holding History

Hussman Strategic Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-84,000	Closed	-$1.09M	–	330
2025 Q3	$1.09M	Buy	+84,000	New	+$1.12M	0.24%	188
2025 Q2	–	Sell	-105,000	Closed	-$1.87M	–	270
2025 Q1	$1.87M	Buy	+105,000	New	+$2.38M	0.45%	87

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Hussman Strategic Advisors's NVCR Position: Q4 2025 in Review

Hussman Strategic Advisors sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 84,000 shares — an estimated $1.09M sold.

Hussman Strategic Advisors first reported a position in NVCR in Q1 2025 and held it in 2 quarters. The position peaked at $1.87M in Q1 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Hussman Strategic Advisors reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Hussman Strategic Advisors sold 84,000 NovoCure shares in Q4 2025, an estimated $1.09M.
Hussman Strategic Advisors first reported a position in NovoCure in Q1 2025 and held it in 2 quarters.
Hussman Strategic Advisors's NovoCure position peaked at $1.87M in Q1 2025.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Hussman Strategic Advisors's 13F filing for Q4 2025, filed 2 Feb 2026.